Showing 3721-3730 of 5621 results for "".
- Nordic Pharma Completes Acquisition of Visant Medical; Plans to Launch Lacrifill in the US for Dry Eye Diseasehttps://modernod.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/Amring Pharmaceuticals, a subsidiary of Nordic Group BV (Nordic Pharma), announced the completion of its acquisition of Visant Medical. Financial terms of the deal were not disclosed. The companies say the acquisition unites Nordic Pharma's pharmaceutical e
- Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/Azura Ophthalmics announced positive topline efficacy and safety results from a phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD). The trial met its prim
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at
- Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplastyhttps://modernod.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT). Belkin describes the Eagle as the first and only contactless l
- Ophtec Launches Precizon Go IOL for Enhanced Intermediate Visionhttps://modernod.com/news/ophtec-launches-precizon-go-iol-for-enhanced-intermediate-vision/2482002/Ophtec announced the launch of the Precizon Go, a hybrid acrylic IOL designed to provide distance and enhanced intermediate vision. The lens is designed to offer natural vision at far and enhanced intermediate vision, without compromising the quality of vision at any
- Optometry Giving Sight Earns Four-Star Rating From Charity Navigatorhttps://modernod.com/news/optometry-giving-sight-earns-four-star-rating-from-charity-navigator/2482001/Optometry Giving Sight (OGS) has announced that its strong financial health and ongoing accountability and transparency have earned a Four-Star rating from Charity Navigator. This rating designates Optometry Giving Sight as an official “Give with Confidence” charity, indicating t
- Zeiss Announces New Biometry Mastery Courses in 2024https://modernod.com/news/zeiss-announces-new-biometry-mastery-courses-in-2024/2482000/Carl Zeiss Meditec is launching the Biometry Mastery Course, a program designed to enhance the skills and expertise of ophthalmic professionals. The Zeiss Biometry Mastery Course is a training initiative aimed at equipping nurses and technicians with advanced knowledge and practica